VERV Verve Therapeutics
- 6.010
- -0.350-5.50%
- 6.150
- +0.140+2.33%
Verve Therapeutics News
Buy Rating Affirmed for Verve Therapeutics Amidst Promising Trials and Strong Financials
Analysts Are Betting On Verve Therapeutics, Inc. (NASDAQ:VERV) With A Big Upgrade This Week
HC Wainwright & Co. Reiterates Buy on Verve Therapeutics, Maintains $15 Price Target
HC Wainwright & Co. analyst Mitchell Kapoor reiterates Verve Therapeutics (NASDAQ:VERV) with a Buy and maintains $15 price target.
Verve Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/09/2024 137.34% HC Wainwright & Co. → $15 Reiterates Buy → Buy 04/03/2024 532.91% Stifel $56 → $40 Main
RBC Capital Keeps Their Buy Rating on Verve Therapeutics (VERV)
Buy Rating for Verve Therapeutics: Financial Stability and Promising Clinical Trials Underpin Growth Potential
Verve Therapeutics' Financial Outlook Threatened by CRISPR Patent Disputes
Buy Rating Affirmed for Verve Therapeutics Amid Progress and Promising Pipeline
Verve Therapeutics (VERV.US): The 2024 Q1 financial report achieved revenue of US$5.695,000, with a previous value of US$1.404 million and an expected value of US$2.02 million; earnings per share were -0.59 dollars, previous value of -0.84 dollars, and ex
Verve Therapeutics (VERV.US): The 2024 Q1 financial report achieved revenue of US$5.695,000, with a previous value of US$1.404 million and an expected value of US$2.02 million; earnings per share were -0.59 dollars, previous value of -0.84 dollars, and expected value of -0.71 dollars.
Verve Therapeutics | 10-Q: Quarterly report
Verve Therapeutics 1Q Rev $5.7M >VERV
Verve Therapeutics 1Q Rev $5.7M >VERV
Verve Therapeutics 1Q Loss/Shr 59c >VERV
Verve Therapeutics 1Q Loss/Shr 59c >VERV
Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2024 Financial Results
First patient dosed in Heart-2 Phase 1b clinical trial of VERVE-102VERVE-201 clinical trial initiation on track for the second half of 2024Received first milestone payment from Eli Lilly for collabora
Verve Therapeutics Announces Dosing of First Patient in Heart-2 Phase 1b Clinical Trial Evaluating VERVE-102
VERVE-102 is an investigational in vivo base editing medicine designed to permanently inactivate the PCSK9 gene in the liver to durably reduce blood low-density lipoprotein cholesterolHeart-2 enrollin
Verve Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, May 03, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing me
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers180 Life Sciences (NASDAQ:ATNF) shares moved upwards by 7.4% to $2.04 during Tuesday's after-market session. The market value of their outstanding shares is at $1.7 million. ABVC BioPharma (NAS
Verve Therapeutics, Inc. (VERV) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages...
Wolf Haldenstein Adler Freeman & Herz LLP Announces That It Is Investigating Verve Therapeutics, Inc. for Potential Violations of Federal Securities Laws
NEW YORK, April 19, 2024 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a preeminent national shareholder rights litigation firm, announces that it is investigating c
Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Quarter
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go
Buy Rating on Verve Therapeutics: Promising Gene Editing Prospects and Anticipated Recovery
Analysis
Price Target
No Data
